Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Immunome, Inc. - Common Stock (NQ:IMNM)

27.41 -0.16 (-0.58%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 31, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,050,738
Open 27.48
Bid (Size) 26.50 (500)
Ask (Size) 29.50 (200)
Prev. Close 27.57
Today's Range 27.00 - 27.63
52wk Range 8.665 - 30.06
Shares Outstanding 87,012,328
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Immunome Reports Second Quarter 2026 Financial Results and Provides Business Update
From Immunome, Inc.
Via Business Wire
News headline image
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Immunome, Inc.
Via Business Wire

Performance

YTD
+31.7%
+31.7%
1 Month
+20.4%
+20.4%
3 Month
+31.9%
+31.9%
6 Month
+23.4%
+23.4%
1 Year
+195.4%
+195.4%

More News

Read More
News headline image
Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-3050, an FAP-Targeted Radioligand Therapy, in Patients with FAP-Expressing Advanced Solid Tumors
From Immunome, Inc.
Via Business Wire
News headline image
What This Immunome Sale Means a Day Before a Big FDA Milestone ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Immunome Announces U.S. FDA Acceptance of New Drug Application for Varegacestat for the Treatment of Adults with Desmoid Tumors
From Immunome, Inc.
Via Business Wire
News headline image
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Immunome, Inc.
Via Business Wire
News headline image
Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-1617, a Potential First-in-Class ADC, in Patients with Advanced Solid Tumors
From Immunome, Inc.
Via Business Wire
News headline image
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Immunome, Inc.
Via Business Wire
News headline image
Immunome Announces Detailed Phase 3 RINGSIDE Data for Varegacestat in Adults with Progressing Desmoid Tumors at the 2026 ASCO Annual Meeting
From Immunome, Inc.
Via Business Wire
News headline image
Immunome to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
From Immunome, Inc.
Via Business Wire
News headline image
Immunome Reports First Quarter 2026 Financial Results and Provides Business Update
From Immunome, Inc.
Via Business Wire
News headline image
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Immunome, Inc.
Via Business Wire
News headline image
Immunome Announces Submission of New Drug Application to U.S. FDA for Varegacestat for the Treatment of Adults with Desmoid Tumors
From Immunome, Inc.
Via Business Wire
News headline image
Immunome Announces Oral Presentation of Phase 3 RINGSIDE Data at 2026 ASCO Annual Meeting
From Immunome, Inc.
Via Business Wire
News headline image
Immunome's Chief Scientist Trimmed His Stake. A Planned FDA Submission Tells You More ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Immunome, Inc.
Via Business Wire
News headline image
ENAVATE's Zenas Bio Pharma add Is a Footnote — The Obexelimab Pipeline Is What to Watch ↗
Via The Motley Fool
News headline image
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Immunome, Inc.
Via Business Wire
News headline image
Investment Manager Fully Exits Immunome Stock in $37.3 Million Sale, According to Latest SEC Filing ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Immunome Reports Full Year 2025 Financial Results and Provides Business Update
From Immunome, Inc.
Via Business Wire
News headline image
Immunome to Present at Upcoming Investor Conferences
From Immunome, Inc.
Via Business Wire
News headline image
Nurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 Million ↗
Via The Motley Fool
News headline image
Biotech-Focused Fund Adds $12 Million to Immunome Bet as Stock Surges 120% ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Investor Slashes $70 Million From Zymeworks as Stock Jumps 60% in a Year ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Biotech Investor Adds $3 Million to Krystal Biotech as Revenue Hits $389 Million in 2025 ↗
Via The Motley Fool
Topics Regulatory Compliance

Frequently Asked Questions

Is Immunome, Inc. - Common Stock publicly traded?
Yes, Immunome, Inc. - Common Stock is publicly traded.
What exchange does Immunome, Inc. - Common Stock trade on?
Immunome, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Immunome, Inc. - Common Stock?
The ticker symbol for Immunome, Inc. - Common Stock is IMNM on the Nasdaq Stock Market
What is the current price of Immunome, Inc. - Common Stock?
The current price of Immunome, Inc. - Common Stock is 27.41
When was Immunome, Inc. - Common Stock last traded?
The last trade of Immunome, Inc. - Common Stock was at 08/31/26 04:00 PM ET
What is the market capitalization of Immunome, Inc. - Common Stock?
The market capitalization of Immunome, Inc. - Common Stock is 2.39B
How many shares of Immunome, Inc. - Common Stock are outstanding?
Immunome, Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.